HK1156250A1 - Unit dosage of apadenoson - Google Patents

Unit dosage of apadenoson

Info

Publication number
HK1156250A1
HK1156250A1 HK11110662.3A HK11110662A HK1156250A1 HK 1156250 A1 HK1156250 A1 HK 1156250A1 HK 11110662 A HK11110662 A HK 11110662A HK 1156250 A1 HK1156250 A1 HK 1156250A1
Authority
HK
Hong Kong
Prior art keywords
apadenoson
unit dosage
dosage
unit
Prior art date
Application number
HK11110662.3A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Hendel
William B Stilley
Shannon P Williams
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Publication of HK1156250A1 publication Critical patent/HK1156250A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK11110662.3A 2008-07-03 2011-10-07 Unit dosage of apadenoson HK1156250A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7816908P 2008-07-03 2008-07-03
US15593709P 2009-02-27 2009-02-27
PCT/US2009/003939 WO2010002473A1 (en) 2008-07-03 2009-07-02 Unit dosage of apadenoson

Publications (1)

Publication Number Publication Date
HK1156250A1 true HK1156250A1 (en) 2012-06-08

Family

ID=41152021

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11110662.3A HK1156250A1 (en) 2008-07-03 2011-10-07 Unit dosage of apadenoson

Country Status (24)

Country Link
US (6) US20100003193A1 (xx)
EP (1) EP2306971B1 (xx)
JP (2) JP2011526894A (xx)
KR (2) KR20140021726A (xx)
CN (1) CN102119023B (xx)
AU (1) AU2009266317B2 (xx)
BR (1) BRPI0913939A2 (xx)
CA (1) CA2729819C (xx)
CY (1) CY1116283T1 (xx)
DK (1) DK2306971T3 (xx)
EA (1) EA022348B1 (xx)
ES (1) ES2537069T3 (xx)
HK (1) HK1156250A1 (xx)
HR (1) HRP20150454T1 (xx)
IL (2) IL210428A (xx)
MX (1) MX2011000193A (xx)
MY (1) MY161655A (xx)
NZ (1) NZ590489A (xx)
PL (1) PL2306971T3 (xx)
PT (1) PT2306971E (xx)
SI (1) SI2306971T1 (xx)
SM (1) SMT201500123B (xx)
WO (1) WO2010002473A1 (xx)
ZA (1) ZA201100163B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415058B2 (en) 2008-07-03 2016-08-16 University Of Virginia Patent Foundation Unit dosage of Apadenoson

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010472A1 (en) 2012-02-03 2015-01-08 Adenobio N.V. Method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE69120840T2 (de) * 1990-02-21 1996-11-21 United Kingdom Government Supraleiter auf Thalliumbasis substituiert durch seltene Erden
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
AU778870B2 (en) 1999-02-01 2004-12-23 University Of Virginia Patent Foundation Compositions for treating inflammatory response
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
AU2001296006A1 (en) * 2000-10-23 2002-05-06 Akedo, Jun Composite structure and method and apparatus for manufacture thereof
US6620645B2 (en) * 2000-11-16 2003-09-16 G.T. Equipment Technologies, Inc Making and connecting bus bars on solar cells
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
ES2277640T3 (es) * 2002-02-27 2007-07-16 Ferring Bv Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
ATE381336T1 (de) 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US6662088B1 (en) * 2002-06-28 2003-12-09 General Electric Company Methods and systems for inspecting aircraft fuselage frames
US7396825B2 (en) 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1729355B1 (en) 2005-06-03 2008-11-19 STMicroelectronics S.r.l. Self-aligned process for manufacturing phase change memory cells
US7767686B2 (en) 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
DE102006022450A1 (de) 2006-05-13 2007-11-15 Lanxess Deutschland Gmbh Wässrige Rußdispersionen für Ink-Jet
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
TW200905703A (en) * 2007-07-27 2009-02-01 Delta Electronics Inc Magnetic device and manufacturing method thereof
US20100003193A1 (en) 2008-07-03 2010-01-07 University Of Virginia Patent Foundation Unit dosage of apadenoson

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415058B2 (en) 2008-07-03 2016-08-16 University Of Virginia Patent Foundation Unit dosage of Apadenoson
US9662406B2 (en) 2008-07-03 2017-05-30 University Of Virginia Patent Foundation Unit dosage of apadenoson

Also Published As

Publication number Publication date
KR20140021726A (ko) 2014-02-20
JP2011526894A (ja) 2011-10-20
US20170007722A1 (en) 2017-01-12
BRPI0913939A2 (pt) 2016-04-26
US20190022253A1 (en) 2019-01-24
SI2306971T1 (sl) 2015-07-31
AU2009266317A1 (en) 2010-01-07
CA2729819C (en) 2014-08-26
IL245577B (en) 2019-05-30
US20100003193A1 (en) 2010-01-07
US9662406B2 (en) 2017-05-30
US20140100185A1 (en) 2014-04-10
JP2013237702A (ja) 2013-11-28
NZ590489A (en) 2013-01-25
IL210428A (en) 2016-05-31
KR20110028531A (ko) 2011-03-18
IL245577A0 (en) 2016-06-30
AU2009266317B2 (en) 2013-12-05
ZA201100163B (en) 2011-09-28
SMT201500123B (it) 2015-09-07
CY1116283T1 (el) 2017-02-08
EP2306971A1 (en) 2011-04-13
CN102119023A (zh) 2011-07-06
IL210428A0 (en) 2011-03-31
PL2306971T3 (pl) 2015-07-31
CA2729819A1 (en) 2010-01-07
US9415058B2 (en) 2016-08-16
PT2306971E (pt) 2015-06-18
MY161655A (en) 2017-04-28
EA201100132A1 (ru) 2011-08-30
US20170252463A1 (en) 2017-09-07
ES2537069T3 (es) 2015-06-02
WO2010002473A1 (en) 2010-01-07
MX2011000193A (es) 2011-03-24
CN102119023B (zh) 2014-04-09
US20130017153A1 (en) 2013-01-17
EA022348B1 (ru) 2015-12-30
HRP20150454T1 (hr) 2015-06-19
EP2306971B1 (en) 2015-02-25
DK2306971T3 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
GB0909680D0 (en) Dosage form
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
GB0806794D0 (en) Therapeutic compounds
GB0813740D0 (en) Therapeutic compounds
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
GB0804755D0 (en) Therapeutic compounds
HK1160925A1 (zh) 組織蛋白酶 的用途
EP2427183A4 (en) THERAPEUTIC COMPOUNDS
GB0803054D0 (en) Medicament
IL245577A0 (en) Dose unit of efdanosone
EP2496704A4 (en) THERAPEUTIC COMPOUNDS
HK1131039A1 (en) Pharmaceutical use of sophoricoside
EP2456309A4 (en) THERAPEUTIC COMPOUNDS
GB0906026D0 (en) Therapeutic compounds
AU2013257527A1 (en) Unit dosage of apadenoson
GB0802576D0 (en) Dosage form
GB0911266D0 (en) Therapeutic compounds
GB0916608D0 (en) Therapeutic compounds
GB0916308D0 (en) Therapeutic compounds
GB0900712D0 (en) Therapeutic compounds
GB0818712D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230629